摘要
目的探讨新诊断2型糖尿病肥胖患者早期联合胰高血糖素样肽-1受体激动剂(glucagon-likepeptide-1receptoragonist,GLP-1)对血糖、胰岛β细胞功能的影响。方法选择2020年3月—2022年5月新沂市中医医院收治的70例新诊断2型糖尿病肥胖患者为研究对象,参考随机数表法分为两组,每组35例。对照组给予胰岛素、二甲双胍治疗,观察组给予胰岛素、二甲双胍、聚乙二醇洛塞那肽治疗。对比两组患者血糖水平、体质指数、血脂、胰岛素抵抗指数(HOMA-IR)、胰岛素β细胞功能指数(HOMA-β)改善情况,及治疗总有效率、不良反应以及随访半年停药率情况。结果治疗后,观察组FPG、HbA1c、BMI均低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组TC、TG、LDL-C均低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组HOMA-IR(2.32±0.20)低于对照组,HOMA-β(69.32±6.23)高于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率(94.29%)高于对照组的77.14%,差异有统计学意义(P<0.05)。两组治疗后不良反应发生率比较,差异无统计学意义(P>0.05);观察组随访半年停药率22.86%高于对照组5.71%,差异有统计学意义(P<0.05)。结论早期联合聚乙二醇洛塞那肽应用在新诊断2型糖尿病肥胖患者,可控制血糖、血脂,改善胰岛功能,控制体质量,效果显著。
Objective To investigate the effects of early combination of glucagon-likepeptide-1receptoragonist(GLP1)on blood glucose and isletβ-cell function in obese patients with newly diagnosed type 2 diabetes mellitus.Methods From March 2020 to May 2022,70 newly diagnosed obese patients with type 2 diabetes who were admitted to Xinyi Traditional Chinese Medicine Hospital were selected as the research objects.They were divided into two groups by reference to the random number table,with 35 cases in each group.The control group was treated with insulin and Metformin,while the observation group was treated with insulin,Metformin and polyethylene glycol Losenatide.The improvement of blood glucose level,body mass index,blood lipid,insulin resistance index(HOMA-IR)and insulinβcell function index(HOMA-β),the total effective rate of treatment,adverse reactions and the half-year follow-up rate of drug withdrawal were compared between the two groups.Results After treatment,the FPG,HbA1c,and BMI of the observation group were lower than those of the control group,the difference was statistically significant(P<0.05).After treatment,the TC,TG,and LDL-C levels in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).After treatment,HOMA-IR(2.32±0.20)in the observation group was lower than that in the control group,HOMA-β(69.32±6.23)was higher than the control group,and the difference was statistically significant(P<0.05).The total effective rate of the observation group(94.29%)was higher than that of the control group(77.14%),the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups after treatment(P>0.05).The sixmonth follow-up discontinuation rate of 22.86%in the observation group was higher than that of 5.71%in the control group,the difference was statistically significant(P<0.05).Conclusion Early combined use of polyethylene glycol Losenatide in newly diagnos
作者
万红霞
曹慧
陈伟
沈大庆
王璐璐
苏晓辉
阴菡菡
WAN Hongxia;CAO Hui;CHEN Wei;SHEN Daqing;WANG Lulu;SU Xiaohui;YIN Hanhan(Department of Endocrinology,Xinyi Hospital of Traditional Chinese Medicine,Xinyi,Jiangsu Province,221400 China)
出处
《糖尿病新世界》
2023年第11期24-27,41,共5页
Diabetes New World Magazine
关键词
2型糖尿病肥胖
聚乙二醇洛塞那肽
血糖
血脂
胰岛素β细胞
Type 2 diabetic obesity
Polyethylene glycol Losenatide
Blood glucose
Blood lipids
Insulinβ-cells
